Prognostic impact of dihydropyrimidine dehydrogenase germline variants in unresectable non-small cell lung cancer patients treated with platin-based chemotherapy

Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several pharmacogenetic variants in patients with unresectab...

Descripción completa

Detalles Bibliográficos
Autores: Guijarro Eguinoa, Francisco Javier, Arjona-Hernández, Sara, Stewart, Stefan, Pernía, Olga, Arias, Pedro, Losantos-Garcia, Itsaso, Rubio, Tania, Burdiel, Miranda, Rodríguez-Antolín, Carlos, Cruz Castellanos, Patricia, Higuera, Oliver, Borobia Pérez, Alberto M., Rodríguez Nóvoa, Sonia María, Castro-Carpeño, Javier de, Ibáñez De Cáceres, Inmaculada, Rosas Alonso, Rocío
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/719587
Acceso en línea:http://hdl.handle.net/10486/719587
https://dx.doi.org/10.3390/ijms24129843
Access Level:acceso abierto
Palabra clave:pharmacogenetics
platinum resistance
cisplatin
carboplatin
non-small cell lung cancer
DPYD
Farmacia
Medicina
Descripción
Sumario:Platin-based chemotherapy is the standard treatment for patients with non-small cell lung cancer (NSCLC). However, resistance to this therapy is a major obstacle in successful treatment. In this study, we aimed to investigate the impact of several pharmacogenetic variants in patients with unresectable NSCLC treated with platin-based chemotherapy. Our results showed that DPYD variant carriers had significantly shorter progression-free survival and overall survival compared to DPYD wild-type patients, whereas DPD deficiency was not associated with a higher incidence of high-grade toxicity. For the first time, our study provides evidence that DPYD gene variants are associated with resistance to platin-based chemotherapy in NSCLC patients. Although further studies are needed to confirm these findings and explore the underlying mechanisms of this association, our results suggest that genetic testing of DPYD variants may be useful for identifying patients at a higher risk of platin-based chemotherapy resistance and might be helpful in guiding future personalized treatment strategies in NSCLC patients

Similares en LA Referencia